Capital Fund Management (CFM)
NVCR icon

Capital Fund Management (CFM)’s NovoCure NVCR Stock Holding History

Capital Fund Management (CFM)’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,500
Closed -$367K – 2090
2024
Q1 		$367K Sell
23,500
-26,100
-53% -$384K ﹤0.01% 1905
2023
Q4 		$741K Buy
+49,600
New +$664K ﹤0.01% 1908
2020
Q1 		– Sell
-2,800
Closed -$236K – 1883
2019
Q4 		$236K Sell
2,800
-16,800
-86% -$1.36M ﹤0.01% 1694
2019
Q3 		$1.47M Buy
19,600
+7,500
+62% +$600K 0.01% 888
2019
Q2 		$765K Buy
+12,100
New +$613K 0.01% 1096

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Quantinno Capital Management
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Capital Fund Management (CFM)'s NVCR Position: Q2 2026 in Review

Capital Fund Management (CFM) increased its NovoCure (NVCR) stake by 49% in Q2 2026, buying an estimated $1.03M and bringing the position to 207,282 shares worth $3.14M. The position accounts for 0.01% of the portfolio, ranked #1164.

Capital Fund Management (CFM) first reported a position in NVCR in Q4 2019 and has held it in 13 quarters since. The position peaked at $4.29M in Q4 2020. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Capital Fund Management (CFM) held 207,282 shares of NovoCure worth $3.14M as of Q2 2026.
  • Capital Fund Management (CFM) bought 67,753 NovoCure shares in Q2 2026, an estimated $1.03M.
  • NovoCure made up 0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1164 holding.
  • Capital Fund Management (CFM) first reported a position in NovoCure in Q4 2019 and has held it in 13 quarters since.
  • Capital Fund Management (CFM)'s NovoCure position peaked at $4.29M in Q4 2020.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.